The information provided in this article is for general informational purposes only. While we endeavour to provide accurate and up-to-date information, there may be instances where information is outdated or incorrect. The contents of this article should not be taken as legal advice nor should it be relied upon in making any business, legal or other decisions. We encourage readers to consult with a qualified legal or professional advisor to obtain proper advice based on your unique circumstances. Cannavigia disclaims any liability for any loss or damage arising out of or in any manner connected with the use of or reliance on the information provided in this article. Note that Cannabis regulations in France are evolving rapidly; always consult the Agence nationale de sécurité du médicament et des produits de santé (ANSM) for updates.
1. Medical cannabis is legal in France through a strict pharmaceutical framework managed by the Agence nationale de sécurité du médicament et des produits de santé (ANSM). The program began as a pilot in March 2021 and transitioned to a permanent national framework on April 1, 2026. However, first prescriptions under the new system remain unlikely before 2027 due to 8-11 month regulatory timelines for product authorization.
2. CBD and industrial hemp products are also legal, provided they contain no more than 0.3% THC, although the sector faces ongoing regulatory uncertainty, particularly around novel food classification and safety assessments.
3. Recreational cannabis remains illegal and criminalized, with simple possession typically resulting in a €200 administrative fine, while unauthorized commercial activities can lead to severe penalties, including up to 10 years imprisonment and fines of up to €7.5 million.
To understand how France's cannabis regulations function in practice, Cannavigia spoke with operators navigating the system at the pharmaceutical level. Hugues Péribère, CEO of Overseed, has spent years building institutional relationships with French health authorities and is currently pursuing market authorization for the company's first three medicinal products as France transitions medical cannabis into common law. His perspective reflects the experience of an operator who has chosen to align with pharmaceutical timelines rather than agricultural or commercial frameworks.
According to Hugues Péribère, CEO of Overseed, a French pharmaceutical cannabis operator, France's framework is built around two distinct pillars: "industrial hemp, which is tightly controlled but permitted for cultivation when THC content remains below 0.3%, and medical cannabis, which has been in a structured experimentation phase for the past few years and is now approaching a pivotal transition into common law." He adds that while the laws are demanding, "they reward seriousness. For operators who treat cannabis as medicine, the regulatory environment is actually coherent."
In this comprehensive guide, we simplify the process of understanding cannabis compliance in France by outlining the regulatory background, applicable fees, and the key steps required to operate within the legal framework. This guide draws on publicly available information from French regulatory authorities including ANSM, DGCCRF, and MILDECA, whose structured transparency has helped shape the responsible development of the country's medical cannabis industry despite its pharmaceutical-centric restrictions, the broader prohibition of recreational cannabis, and the recent EFSA provisional safety limit of 2 mg/day for CBD that has further complicated the hemp-derived products market.
· History of cannabis in France
· Cannabis laws in France
· Cannabis compliance & ongoing Regulatory Requirements in France
· Cannabis business opportunities in France
Although the ancient history of hemp in Western Europe is poorly documented, archaeological findings from the Late Iron Age site of Al Poux in southwestern France indicate that cannabis may have been cultivated as early as pre-Roman times, possibly along riverbanks or processed through retting in nearby water sources. By the early medieval period, cannabis was cultivated primarily for textile fiber (hemp), quickly becoming a critical resource for maritime industries. Its durability and resistance to saltwater made it indispensable for French naval ropes and sails.
By the nineteenth century, France had become Europe’s leading hemp producer, cultivating over 200,000 hectares at its peak. Industrial use dominated, with textile centers like Lille and Rouen processing hemp into rope, canvas, and clothing. During this same period, cannabis in its resin form (hashish) entered French society through colonial expansion, particularly following Napoleon's Egyptian campaign, which exposed French soldiers and intellectuals to its psychoactive properties. Following an 1846-1840 journey throughout North Africa and the Middle East, French physician Jacques-Joseph Moreau wrote on the psychological effects of cannabis use. Moreau was a member of Paris' Club des Hashischins (founded in 1844). During the same period, cannabis gained popularity among Persian elites including figures such as Victor Hugo, Honoré de Balzac, and Charles Baudelaire, who participated in the Club des Hashischins. Despite this cultural experimentation, cannabis remained largely unregulated, and industrial hemp continued to dominate production.
The shift toward prohibition began in the early twentieth century. In 1916, the French military banned cannabis use among soldiers during World War I, citing concerns about discipline. This marked the beginning of institutional control over the substance. On July 12, 1916, the first law that openly prohibited marijuana consumption was issued, describing cannabis as a poisonous substance. These early measures aligned with emerging international drug control efforts and laid the groundwork for stricter national policies, even as industrial hemp cultivation continued to decline due to competition from synthetic fibers.
France’s modern cannabis policy was firmly established with Law No 70-1320 of December 31, 1970, which created one of the strictest narcotics frameworks in Europe. This legislation criminalized possession, use, and trafficking while establishing enforcement structures that continue to operate today, including institutions such as MILDECA (Mission interministérielle de lutte contre les drogues et les conduites addictives). Despite growing reform movements across Europe in the late twentieth and early twenty-first centuries, France maintained a prohibitionist stance. While countries like the Netherlands and Spain adopted more liberal approaches, France intensified enforcement, culminating in the introduction of a €200 administrative fine in 2020 for simple possession rather than full decriminalization.
The modern era of medical cannabis in France began in 2021 with the launch of a pilot program overseen by ANSM. The program aimed to evaluate the safety and feasibility of cannabis-based treatments for a limited number of patients. Enrollment peaked at approximately 3,000 patients but declined significantly over time due to access barriers and product limitations, reaching around 700 patients by 2026. The pilot officially concluded in March 2026 and transitioned into a permanent pharmaceutical framework on April 1, 2026. However, strict regulatory requirements such as full marketing authorization and compliance with EU pharmaceutical standards mean that new patient access is not expected until 2027, creating a temporary gap in availability.
Recent developments between 2024 and 2026 indicate a tightening rather than a loosening of cannabis regulations in France. Authorities have banned several semi-synthetic cannabinoids and increased scrutiny of CBD products, with agencies such as ANSES (Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail) and European Food Safety Authority (EFSA) introducing stricter safety and intake guidelines. At the same time, enforcement against non-compliant imports has intensified, reflecting a broader effort to control the rapidly expanding cannabinoid market.
Looking beyond 2026, France is expected to enter a transitional regulatory phase. The permanent medical cannabis framework is now in place, but real market activity will depend on product approvals by the ANSM, with the first wave of authorized products anticipated around 2027. This creates a short-term access gap but signals a shift toward a fully pharmaceuticalized cannabis model. At the EU level, ongoing discussions around CBD classification, novel food approvals, and harmonized cannabinoid regulations are likely to shape France’s next policy direction. While no legislative movement toward recreational legalization is currently underway, increasing pressure from neighboring markets and evolving EU standards may influence future reforms.
Recreational cannabis remains illegal in France as of April 2026, with no legal pathway for personal use, possession, cultivation, or sale. The €200 administrative fine system introduced in 2020 does not legalize or decriminalize cannabis; instead, it streamlines enforcement by replacing criminal prosecution for minor possession with a fixed penalty while maintaining full prohibition under the French Public Health Code.
Under current law, possession of small quantities (typically up to 10 grams) is punishable by a €200 administrative fine, which may be reduced to €150 if paid promptly (within 15 days) or increased to €450 if unpaid within 45 days. Public consumption carries the same penalty. However, possession of larger quantities or cases involving aggravating circumstances can lead to criminal prosecution, with penalties of up to one-year imprisonment and a €3,750 fine.
French law also imposes harsher penalties under specific aggravating circumstances. These include use or possession near schools, consumption in public establishments such as bars or transport systems, use while operating any vehicle, involvement of minors, and cross-border activity. In such cases, even minor possession can escalate from an administrative fine to full criminal prosecution.
Enforcement is centrally coordinated by MILDECA, which operates under the authority of the Prime Minister and maintains a zero-tolerance approach to recreational cannabis. The administrative fine system has improved efficiency but has not reduced enforcement intensity.
From a judicial perspective, the Council of State upheld cannabis prohibition in a 2023 ruling, confirming that its classification as a controlled substance is consistent with public health objectives. As of April 2026, there are no active legal challenges expected to alter this framework.
Politically, the administration of Emmanuel Macron continues to oppose recreational cannabis legalization. Despite policy shifts in other European countries, France has no active legislation under consideration to legalize or decriminalize cannabis beyond the existing fine system.
Medical cannabis is legal in France as of April 2026, operating under a permanent pharmaceutical framework that replaced the national pilot program on April 1, 2026. However, despite its legal status, access remains highly restricted. Treatment is limited to hospital-initiated prescriptions, reserved for patients who have failed standard therapies, and confined to a narrow set of approved conditions.
The framework is overseen by the ANSM, which regulates all aspects of authorization, prescribing, and product compliance. Medical cannabis products must obtain either a full Marketing Authorization (MA) or a Temporary Use Authorization (ATU), both of which require extensive pharmaceutical-grade documentation and review. As a result, the approval process typically takes 8 to 11 months, delaying widespread patient access.
As of April 2026, medical cannabis can only be prescribed for five specific indications: neuropathic pain resistant to standard treatment, drug-resistant epilepsy, oncology supportive care (such as chemotherapy-related side effects), palliative care, and multiple sclerosis spasticity. ANSM retains exclusive authority to expand or modify this list, and no additional conditions are currently approved.
Strict product and administration requirements further limit access. All medical cannabis products must be manufactured in compliance with EU Good Manufacturing Practice (GMP) standards and adhere to predefined THC and CBD ratios approved by ANSM. Administration is restricted to oral or sublingual forms, while smoking is explicitly prohibited. Inhalation is only permitted through certified medical vaporizers (CE-certified), and all products must meet stringent packaging and safety standards.
Despite the framework being active, new patient access is currently suspended. The pilot program, which ended on March 31, 2026, left approximately 700 transitional patients who continue to receive treatment under temporary provisions. However, no new prescriptions are expected until authorized products complete the regulatory process, which is anticipated in 2027.
Reimbursement remains another unresolved issue. The Haute Autorité de Santé (HAS) is currently evaluating whether medical cannabis should be covered under the national healthcare system. As of April 2026, no reimbursement framework has been approved, although transitional patients continue to receive treatment at no cost under temporary arrangements.
Cannabis cultivation in France is strictly regulated and largely prohibited, with legality depending on the intended use and THC content. As of April 2026, cultivation of high-THC cannabis (recreational or unauthorized medical use) is illegal and treated as a serious criminal offense, while limited cultivation of industrial hemp and tightly controlled medical cannabis is permitted under specific regulatory frameworks.
For recreational purposes, all cannabis cultivation is illegal, regardless of quantity or intent. Even a single plant grown for personal use can trigger criminal prosecution, with penalties of up to 10 years’ imprisonment and €7.5 million in fines. French law makes no distinction between personal and commercial cultivation in this context, reflecting a zero-tolerance approach.
In contrast, industrial hemp cultivation is legal but subject to strict compliance requirements. Only approved hemp varieties listed in the EU Common Catalogue may be cultivated, and the THC content must not exceed 0.3%. The French catalog has 9 varieties of hemp also registered in the EU catalog which has 49 varieties. Some of the varieties include Uso 31, Férimon, Fédora 17, Félina 32, Santhica 27, Epsilon 68, Futura 75, Fibror 79 and Dioïca 88.
Farmers must use certified seeds and comply with agricultural and regulatory standards governing traceability and production. Hemp cultivation is limited to industrial purposes such as fiber, seeds, and certain CBD applications, and any deviation from these conditions can result in criminal liability.
Medical cannabis cultivation is also permitted but only within a highly controlled pharmaceutical framework overseen by the ANSM. Cultivation is restricted to authorized pharmaceutical operators and must take place in secure indoor facilities that meet stringent regulatory and security requirements. Growers are required to comply with Good Agricultural and Collection Practices (GACP) and operate in partnership with licensed pharmaceutical establishments. Independent or small-scale cultivation for medical purposes is not permitted.
All cultivation activities, whether hemp or medical, are subject to inspection and oversight, with strict documentation and traceability requirements. Unauthorized cultivation, including exceeding THC limits, using non-approved seed varieties, or operating without proper authorization, is treated as a criminal offense and may result in severe penalties, including imprisonment and substantial fines.
Cannabis import and export in France is strictly controlled and highly restricted, with legality dependent on product classification (medical cannabis vs. hemp/CBD) and prior authorization from national regulators. As of March 2026, cross-border movement of cannabis products is permitted only within tightly regulated frameworks, with severe penalties for non-compliance.
For medical cannabis, importation is allowed but requires prior approval from the ANSM, along with clearance from French Customs authorities. Products must meet pharmaceutical-grade standards, including EU Good Manufacturing Practice (GMP) compliance, and must be intended for authorized medical use under the national framework.
Export of medical cannabis from France is permitted but highly restricted, and may only occur where the destination country operates a recognized medical cannabis or pharmaceutical regulatory framework. In practice, exports are limited to jurisdictions with established compliance systems and, in many cases, formal bilateral agreements or mutual recognition standards. These typically include EU member states with medical cannabis programs such as Germany, Italy, Spain, Portugal, and Netherlands, as well as select international markets like Canada and Australia, where medical cannabis is federally regulated.
For industrial hemp and CBD products, import and export are legal in principle but remain subject to strict conditions. Products must comply with the ≤0.3% THC limit, be derived from approved hemp varieties, and meet all applicable EU and French regulations, including rules governing food, cosmetics, and consumer safety. However, regulatory uncertainty, particularly around ingestible CBD products, has increased scrutiny at borders, with authorities closely monitoring compliance.
French Customs, operating under the Directorate General of Customs and Indirect Duties (DGDDI), plays a central role in enforcement, conducting inspections and seizing non-compliant goods. Cross-border e-commerce shipments are also subject to heightened monitoring, especially following recent EU-level actions targeting unapproved cannabinoid products.
Unauthorized importation or exportation of cannabis whether recreational, medical, or non-compliant CBD can result in severe criminal penalties, including up to 10 years’ imprisonment and €7.5 million in fines, particularly where trafficking elements are involved. Even administrative violations, such as incorrect documentation or THC misclassification, can lead to product seizure, financial penalties, and regulatory sanctions.
Cannabis operations in France involve significant regulatory costs, which vary depending on the business model. As of March 2026, fees fall into three main categories: medical cannabis pharmaceutical authorizations, industrial hemp and CBD compliance, and import/export licensing. All fees are payable to French or EU regulatory bodies and are non-refundable, even if an application is rejected.
Getting a cannabis license in France depends on the type of activity (medical cannabis, hemp/CBD, or import/export). France does not offer a single “cannabis license.” Instead, you must follow different regulatory pathways, primarily through the ANSM and other authorities.
Below is a clear, step-by-step guide based on current law.
The licensing process requires more than box-checking. According to Hugues Péribère, "It has been a multi-year journey, and one we approached with a long-term mindset from the very beginning." He notes that Overseed has "built genuine credibility and legitimacy with French health authorities" over years of engagement. "The process is not easy — it demands scientific depth, operational transparency, and sustained engagement with regulators. But we see this not as a burden, but as a competitive moat. The relationships and institutional trust we have built are not easily replicated."
Applying for cannabis-related authorization in France is a highly technical and compliance-driven process. Many applications are delayed or rejected due to avoidable errors. The following are the most common pitfalls businesses should address before submitting an application.
1. Misclassifying the Business Activity
One of the most frequent mistakes is failing to correctly define the scope of operations. Confusing medical cannabis with CBD or industrial hemp can result in applying under the wrong regulatory framework, leading to immediate rejection or significant delays.
2. Incomplete or Weak Application Dossiers
Applications submitted to the ANSM require comprehensive technical documentation, including product specifications, safety data, and quality control procedures. Incomplete or poorly structured dossiers are a primary cause of rejection.
3. Failure to Meet Pharmaceutical Standards
For medical cannabis, applicants often underestimate the level of compliance required. Failure to meet EU pharmaceutical standards, including Good Manufacturing Practice (GMP), traceability, and pharmacovigilance systems, can prevent approval entirely.
4. Non-Compliance with THC Limits and Approved Inputs
In hemp and CBD operations, exceeding the 0.3% THC limit or using non-approved seed varieties can result in application denial, product seizure, or legal penalties. Strict adherence to EU-approved inputs is essential.
5. Ignoring Product Classification Rules
CBD products must be correctly classified (e.g., cosmetic vs. ingestible). Attempting to register ingestible CBD products without meeting EU novel food requirements, or during periods of regulatory uncertainty, can halt the application process.
6. Lack of a Local or EU-Compliant Entity
Applications submitted without a properly registered legal entity within France or the EU are not considered valid. Many foreign operators overlook this requirement, leading to structural ineligibility.
7. Inadequate Preparation for Inspections
Regulatory authorities may conduct facility inspections as part of the approval process. Failure to demonstrate operational readiness, proper documentation, or compliance systems during inspection can result in delays or refusal.
8. Underestimating Timelines and Regulatory Complexity
Applicants often assume faster approval timelines than are realistically achievable. The French system involves multiple layers of review, and insufficient planning for regulatory timelines can disrupt market entry strategies.
9. Unauthorized Changes During the Application Process
Making changes to products, processes, or facilities after submission without notifying the relevant authority can invalidate the application or require resubmission. All modifications must be formally approved.
10. Weak Compliance Strategy Post-Approval
Securing authorization is only the beginning. Businesses that fail to plan for ongoing compliance, including reporting obligations and regulatory updates, risk suspension or revocation of their authorization.
Operating within France’s cannabis framework requires continuous regulatory readiness, particularly in relation to audits, facility security, and documentation. Authorities such as the ANSM and customs bodies expect operators to maintain strict compliance at all times, not only during initial licensing.
The daily reality of maintaining compliance involves navigating tension between market speed and regulatory rigor. According to Péribère, "The core challenge is operating at the intersection of two worlds that are not always synchronized: the speed of a developing market and the deliberate pace of pharmaceutical regulation." He explains that Overseed made a deliberate choice to "align ourselves with the pharmaceutical timeline, because that is where durable value and patient trust are built." This means, he says, that "every batch, every process, every supplier relationship is held to pharmaceutical-grade requirements. That creates complexity and cost, but it is non-negotiable for us."
Cannabis operators must be prepared for both scheduled and unannounced inspections. Regulatory audits typically assess compliance with authorization conditions, product quality standards, and operational procedures. Businesses are expected to maintain audit-ready systems, including up-to-date documentation, validated processes, and clearly defined standard operating procedures (SOPs).
For medical cannabis, audit requirements align with pharmaceutical standards, meaning companies must demonstrate full compliance with Good Manufacturing Practice (GMP), including batch traceability, deviation management, and quality assurance systems. Failure to meet audit requirements can result in suspension or revocation of authorization.
Strict security protocols are required across all cannabis-related operations, particularly for medical cannabis and controlled substances. Facilities must implement robust physical and operational security measures to prevent unauthorized access, diversion, or theft. These measures typically include controlled access systems, surveillance monitoring, secure storage areas, and restricted handling procedures. For medical cannabis cultivation and processing, security requirements are reinforced by regulatory oversight and must align with pharmaceutical handling standards.
Cross-border operations are also subject to heightened scrutiny, with customs authorities enforcing strict controls on the movement of cannabis products. Any gaps in security or documentation during transport may lead to seizure or enforcement action.
Accurate and comprehensive record keeping is a core compliance requirement. Operators must maintain detailed records covering all aspects of their activities, including sourcing, production, storage, distribution, and disposal.
Traceability is particularly critical for medical cannabis, where each batch must be fully documented from origin to end use. This includes maintaining records of product composition, testing results, and distribution channels. Documentation must be readily accessible for inspection and retained in accordance with regulatory requirements. See our Cannavigia modules for more information on how we can help you maintain compliance and track data in real time.
All cannabis-related products must include clear, accurate, and non-misleading labeling. For medical cannabis, labeling must comply with pharmaceutical standards, including detailed information on composition, dosage, method of administration, batch identification, and safety warnings. Products must also reflect the exact specifications approved during the authorization process.
For hemp and CBD products, labeling must accurately indicate THC content (not exceeding 0.3%), ingredient composition, and intended use. Mislabeling, particularly regarding cannabinoid content or product classification, can lead to product seizure and regulatory sanctions.
CBD products classified as cosmetics must comply with EU cosmetic labeling rules, including ingredient disclosure, safety information, and responsible person identification. Any claims made on the label must be substantiated and aligned with the product’s approved use.
Advertising of cannabis-related products in France is highly restricted. Medical cannabis promotion is subject to pharmaceutical advertising controls, meaning that any promotional material must comply with strict regulatory oversight and, in some cases, require prior approval from the ANSM.
For CBD and hemp products, advertising must not include medical or therapeutic claims unless the product has received proper pharmaceutical authorization. Marketing content must avoid misleading consumers about the effects, benefits, or legal status of the product.
Additionally, advertising must not target minors or encourage recreational cannabis use. Any association with psychoactive effects or recreational consumption can trigger enforcement action.
Testing is a critical component of cannabis regulation in France. Products must undergo laboratory analysis to verify cannabinoid content, ensure THC compliance, and confirm the absence of contaminants such as pesticides, heavy metals, and microbiological impurities.
For medical cannabis, testing must meet pharmaceutical-grade standards, with validated methods and documented quality control processes. Batch testing and release procedures must be in place to ensure consistency and safety.
Hemp and CBD products must also be tested to confirm compliance with THC limits and product specifications. Authorities may conduct independent testing, particularly in cases of import/export or market surveillance.
For pharmaceutical operators, testing goes well beyond the 0.3% THC threshold that governs industrial hemp. According to Péribère, "We do not operate under a fixed THC limit. Instead, our products are meticulously characterised and titrated, with pharmacological data defined within a comprehensive medicinal dossier." He emphasizes that this dossier "fully satisfies the requirements applicable to all medicines granted market access, covering both active substances and manufacturing processes," and that "each finished product is supported by robust stability studies and thorough pharmacokinetic analyses, ensuring the highest standards of quality and safety are consistently met."
Failure to comply with cannabis regulations in France can result in severe legal, financial, and operational consequences. Enforcement is strict and applies across all segments of the industry, including medical cannabis, industrial hemp, CBD products, and cross-border activities. Authorities such as the ANSM, customs, and law enforcement agencies actively monitor compliance and take action against violations.
Unauthorized activities involving cannabis are treated as serious criminal offenses. This includes illegal cultivation, distribution, importation, or possession outside permitted frameworks. Offenses may lead to significant fines and imprisonment, particularly in cases involving trafficking or organized activity. Even administrative violations can escalate into criminal proceedings where intent or scale is established.
Non-compliant products may be immediately seized or removed from the market. This applies to products that exceed THC limits, are improperly labeled, or fail to meet regulatory standards. In many cases, authorities may also order product destruction, resulting in direct financial losses and supply chain disruption.
Operators who fail to meet regulatory requirements risk suspension or revocation of their authorization. This may follow failed inspections, non-compliance with quality standards, or failure to meet reporting obligations. Once revoked, regaining authorization can be difficult and may require a full reapplication process.
Non-compliance can result in substantial financial losses beyond direct penalties. Businesses may face recall costs, legal expenses, contract termination, and loss of market access. Operational disruptions, including halted production or blocked imports, can significantly affect business continuity.
For import and export activities, non-compliance can trigger customs enforcement actions, including shipment seizures and restrictions on future trade. Repeated violations may lead to increased scrutiny or blacklisting by regulatory authorities.
France represents one of Europe’s most complex yet potentially lucrative cannabis markets. While the regulatory environment remains restrictive, particularly for recreational use, the country’s pharmaceutical infrastructure, large population, and leadership in industrial hemp create significant long-term opportunities across multiple segments.
France is currently the third largest industrial hemp producer in the world and largest producer in Europe, accounting for more than 60% of total EU hemp production, with over 20,000 hectares under cultivation. This positions the country as a dominant player in the global hemp supply chain. The hempcrete market in France is expected to reach a projected revenue of US$ 2,169.0 million by 2030.
The broader French cannabis market, including medical and CBD segments, is projected to grow steadily as regulatory frameworks evolve. Europe’s medical cannabis market is expected to exceed €10 billion by 2030, with France anticipated to capture a significant share once patient access expands under its pharmaceutical model.
However, due to the transition to the permanent framework managed by the ANSM, commercial medical cannabis activity is expected to scale meaningfully from 2027 onward, following product authorizations.
Not all operators view the 2026 transition equally. According to Péribère, "For Overseed, the transition of medical cannabis into common law in France is unambiguously an opportunity — and one we have been preparing for with precision." He notes that when the transition occurs, Overseed's three initial products will enter market authorization evaluation while the company obtains "the status of établissement pharmaceutique fabricant — a pharmaceutical manufacturing establishment — which is the formal recognition of everything we have built." He draws a sharp distinction between approaches: "Companies that have treated medical cannabis primarily as a commercial opportunity may find the 2026 framework burdensome. For those of us who have always treated it as medicine, and built our operations accordingly, it is the moment where our approach is validated by the regulatory system itself."
France has one of the highest cannabis consumption rates in Europe, with an estimated 10–11 million people having used cannabis at least once and around 900,000 regular users, despite its illegal status.
On the medical side, the pilot program (2021–2026) enrolled approximately 3,000 patients at its peak, although participation declined to around 700 patients by early 2026 due to access limitations. This highlights both existing demand and structural barriers within the current system.
As access improves under the permanent pharmaceutical framework, demand is expected to expand significantly, particularly for conditions such as chronic pain, epilepsy, and multiple sclerosis.
France’s export strength lies primarily in industrial hemp and pharmaceutical-grade production capabilities. As Europe’s leading hemp producer, the country already exports raw materials for textiles, construction, food ingredients, and cosmetics across the EU.
With the implementation of a pharmaceutical cannabis framework, France also has the potential to become a high-quality exporter of medical cannabis products, particularly if domestic cultivation and manufacturing scale under EU Good Manufacturing Practice (GMP) standards.
However, export activity for medical cannabis remains limited in the short term, as product authorization and domestic supply chains are still under development.
Despite regulatory constraints, several investment opportunities are emerging within the French cannabis sector:
· Pharmaceutical-grade medical cannabis (pre-2027 positioning)
· CBD cosmetics and topical products, which remain legally viable
· Industrial hemp applications, including textiles, bioplastics, and construction materials
· Supply chain infrastructure, including processing, storage, and distribution
· Research and clinical development, particularly within the pharmaceutical framework
1. Can I travel to France with CBD gummies?
Traveling to France with CBD gummies is legally risky and generally not recommended. While CBD is legal if it contains no more than 0.3% THC, ingestible CBD products face ongoing regulatory uncertainty. Authorities such as the ANSM and ANSES closely monitor these products, and customs may seize them even if compliant. In contrast, hemp seeds, fiber, and flour are permitted under EU rules. However, CBD flower and raw plant materials remain prohibited for import. To avoid delays or confiscation, travelers are advised not to bring CBD gummies into France.
2. Can I bring medical cannabis into France?
Bringing medical cannabis into France is highly restricted and generally not permitted without prior authorization. Even if you have a valid prescription from another country, French law requires approval from the ANSM before importing any cannabis-based medicine. Without this authorization, medical cannabis may be confiscated at the border, and travelers could face legal consequences. France’s medical cannabis system operates under a controlled pharmaceutical framework, meaning only approved products can be used within the country. Travelers should consult authorities before attempting to carry medical cannabis into France.
3. Can I buy CBD products in France?
Yes, CBD products are available in France, but only under strict conditions. Products must be derived from approved hemp varieties and contain no more than 0.3% THC. CBD cosmetics and topicals are widely sold, while ingestible products such as oils and edibles face regulatory uncertainty and increased scrutiny from authorities like ANSES. Consumers should purchase from reputable retailers that provide lab testing and clear labeling. CBD flower and raw plant materials are not permitted for sale or import, even if THC levels are compliant.
4. Can foreigners start a cannabis business in France?
Yes, foreigners can enter the French cannabis market, but they must establish a legal entity within France or the European Union. Regulatory approvals are activity-specific and often require compliance with strict standards set by the ANSM and other authorities. Medical cannabis businesses must meet pharmaceutical-grade requirements, while hemp and CBD operations must comply with EU agricultural and product regulations. Due to the complexity of the system, foreign operators typically partner with local entities to navigate licensing and compliance requirements effectively.
5. Can I grow cannabis at home in France?
No, growing cannabis at home in France is illegal, regardless of quantity or purpose. French law does not distinguish between personal and commercial cultivation when it comes to high-THC cannabis. Unauthorized cultivation can result in severe criminal penalties, including fines and imprisonment. Only industrial hemp cultivation is permitted, and this is strictly limited to approved seed varieties with THC levels not exceeding 0.3%. Medical cannabis cultivation is allowed only under tightly controlled pharmaceutical authorization and cannot be carried out by individuals. As a result, home growing remains prohibited under current French law.
1. ANSM. “Dossier Thématique - Mise En Place de l’Expérimentation Du Cann - ANSM.” ANSM, 2024, ansm.sante.fr/dossiers-thematiques/cannabis-a-usage-medical/mise-en-place-de-lexperimentation-du-cannabis-medical. Accessed 8 Apr. 2026.
2. “Marketing Authorisation for Medicines - ANSM.” ANSM, ANSM, 2022, ansm.sante.fr/page/marketing-authorisation-for-medicines.
3. Bouby, Laurent. “Le Chanvre (Cannabis Sativa L.) : Une Plante Cultivée à La Fin de l’Âge Du Fer En France Du Sud-Ouest ?” Comptes Rendus Palevol, vol. 1, no. 2, Jan. 2002, pp. 89–95, https://doi.org/10.1016/s1631-0683(02)00015-5. Accessed 13 Apr. 2021.
4. Business of Cannabis. “Delayed but Not Denied: France Unveils Full Medical Cannabis Blueprint.” Cannabis Health News, 27 Mar. 2025, cannabishealthnews.co.uk/2025/03/27/france-unveils-full-medical-cannabis-blueprint/.
5. Cannabis Europa. “Is Cannabis Legal in Europe? - Cannabis Europa.” Cannabis Europa, 2 Apr. 2026, cannabis-europa.com/is-cannabis-legal-in-europe/. Accessed 8 Apr. 2026.
6. Cannavigia. “Cannabis Compliance in the Netherlands – Background Info, Fees & How-to Checklist [FREE LICENSING GUIDE] - Cannavigia.” Cannavigia.com, 2024, www.cannavigia.com/blog-posts/cannabis-country-report-netherlands-how-to-get-a-cannabis-license.
7. CANNAVIGIA - Our Solutions.” Cannavigia.com, 2020, www.cannavigia.com/solutions.
8. Casassus, Barbara. “French Medicine Regulator Bans Two Cannabinoid Derivatives after Reported Side Effects.” BMJ, 6 June 2024, p. q1249, https://doi.org/10.1136/bmj.q1249. Accessed 23 Sept. 2024.
9. Cevidra. “AAC | Compassionate Access Authorisation | Cevidra.” Cevidra, 27 Feb. 2026, www.cevidra.com/faq-items/aac-autorisation-dacces-compassionnel-compassionate-access-authorisation/. Accessed 8 Apr. 2026.
10. “What Is the Early Access Program (AAP) in France? | Cevidra.” Cevidra, 29 Oct. 2025, www.cevidra.com/faq-items/what-is-the-early-access-program-aap-in-france/. Accessed 8 Apr. 2026.
11. Chambers and Partners. “Comparisons | Global Practice Guides | Chambers and Partners.” Chambers.com, 2025, practiceguides.chambers.com/practice-guides/comparison/1003/16301/25531-25538-25540. Accessed 8 Apr. 2026.
12. DUNDAS, Mairead, et al. “Down to Earth - Can Hemp Help Save the Planet?” France 24, FRANCE 24, 4 Dec. 2020, www.france24.com/en/tv-shows/down-to-earth/20201204-can-hemp-help-save-the-planet. Accessed 8 Apr. 2026.
13. ECA Academy. “French Cannabis Specifications and Quality Requirements.” Gmp-Compliance.org, ECA Academy, 11 Nov. 2020, www.gmp-compliance.org/gmp-news/french-cannabis-specifications-and-quality-requirements. Accessed 8 Apr. 2026.
14. Ecomundo. “EU Cosmetic Regulation 1223/2009: Key Compliance Guide.” Ecomundo.eu, 2017, www.ecomundo.eu/en/blog/eu-cosmetic-regulation-1223-2009-key-compliance-guide.
15. EFSA. “Provisional Safe Level for Cannabidiol as a Novel Food.” European Food Safety Authority, 9 Feb. 2026, www.efsa.europa.eu/en/news/provisional-safe-level-cannabidiol-novel-food.
16. EMA. “Good Manufacturing Practice | European Medicines Agency.” Www.ema.europa.eu, 2024, www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice.
17. Eu. HEMP SEED CATALOGUE 2024.
18. EUDA. “Cannabis – the Current Situation in Europe (European Drug Report 2025) | Www.euda.europa.eu.” Europa.eu, 2025, www.euda.europa.eu/publications/european-drug-report/2025/cannabis_en.
19. EuroPages. “Hemp Manufacturer/Producer France | B2B Companies and Suppliers | Europages.” Europages.co.uk, 2021, www.europages.co.uk/companies/france/manufacturer%20producer/hemp.html. Accessed 8 Apr. 2026.
20. European Commission. “Hemp.” Agriculture.ec.europa.eu, agriculture.ec.europa.eu/farming/crop-productions-and-plant-based-products/hemp_en.
21. French Academy of Medicine. “Legalizing “Recreational” Cannabis Use Would Cause Serious Public Health Problems – Académie Nationale de Médecine | Une Institution Dans Son Temps.” Academie-Medecine.fr, 2025, www.academie-medecine.fr/legalizing-recreational-cannabis-use-would-cause-serious-public-health-problems/?lang=en.
22. Grandview Research. “France Hempcrete Market Size & Outlook, 2030.” Grandviewresearch.com, 2026, www.grandviewresearch.com/horizon/outlook/hempcrete-market/france. Accessed 8 Apr. 2026.
23. Green, Johnny. “France Sets 2027 Medical Cannabis Timetable.” International Cannabis Business Conference, 23 Feb. 2026, internationalcbc.com/france-sets-2027-medical-cannabis-timetable/. Accessed 8 Apr. 2026.
24. Hoban, Robert. “Europe’s Green Horizon for Medical Cannabis and Hemp.” Forbes, 12 Aug. 2025, www.forbes.com/sites/roberthoban/2025/08/12/truckin-to-2030-europes-green-horizon-for-medical-cannabis--hemp/.
25. João Xabregas, and João Xabregas. “France: Macron Does Not Want to Move Forward with Medicinal Cannabis in 2024.” CannaReporter, 4 Oct. 2023, cannareporter.eu/en/2023/10/04/Franca-Macron-will-not-move-forward-with-medical-cannabis-in-2024/.
26. Omnes, Marie-Anne, and Kathryn Snipes. THIS REPORT CONTAINS ASSESSMENTS of COMMODITY and TRADE ISSUES MADE by USDA STAFF and NOT NECESSARILY STATEMENTS of OFFICIAL U.S. GOVERNMENT POLICY Voluntary Report -Voluntary -Public Distribution. 2021.
27. Price, Stephanie. “EFSA Puts CBD Novel Foods Evaluations on Hold due to Lack of Data.” Business of Cannabis, 10 June 2022, businessofcannabis.com/efsa-cbd-novel-foods-evaluations-hold-data/. Accessed 8 Apr. 2026.
28. Prohibition Partners. “Is Cannabis Legal in France? - Cannabis Europa.” Cannabis Europa, 7 Apr. 2026, cannabis-europa.com/insights/is-cannabis-legal-in-france/. Accessed 8 Apr. 2026.
29. Seeds, Dinafem. “France, 100 Years of Cannabis Prohibition in the Gallic Country.” Dinafem.org, 2016, www.dinafem.org/en/blog/cannabis-prohibition-france/.
30. Service Public. “Therapeutic Cannabis.” Gouv.fr, 2025, www.service-public.gouv.fr/particuliers/vosdroits/F35817?lang=en. Accessed 8 Apr. 2026.
31. Stevens, Ben. “Cannabis Europa Paris 2026: French Reimbursement Revealed.” Business of Cannabis, 19 Feb. 2026, businessofcannabis.com/cannabis-europa-paris-2026-frances-medical-cannabis-reimbursement-plans-revealed/. Accessed 8 Apr. 2026.
32. “Why Cannabis Companies Are Betting on Medical Vaporisers.” Business of Cannabis, 29 Jan. 2026, businessofcannabis.com/is-europe-moving-away-from-cannabis-flower-why-companies-are-betting-on-ce-certified-devices/. Accessed 8 Apr. 2026.
33. UNODC. E/5082 E/CN.7/544 COMMISSION on NARCOTIC DRUGS REPORT of the TWENTY-FOURTH SESSION ECONOMIC and SOCIAL COUNCIL Official Records: Fifty-Second Session UNITED NATIONS. 1971.
